Zenagem

Zenagem is a chemoproteomics-first biotechnology company focused on drugging the 'undruggable' proteome. The company utilizes a patented hydrazine probe platform to identify and target electrophilic cofactors and radical mechanisms that traditional drug discovery platforms often overlook. By mapping proteome-wide engagement in native environments, Zenagem aims to accelerate the discovery of first-in-class inhibitors for high-need indications. The company's technology is based on the research of co-founder Dr. Megan Matthews at the University of Pennsylvania. Zenagem prioritizes therapeutic areas where its platform can uniquely address disease biology, specifically pregnancy-related disorders (preeclampsia), aggressive cancers (glioblastoma), and infections where cofactor-dependent metabolism is central to the disease pathology.